Fluoroquinolone use and aortic aneurysm or dissection: a German cohort study based on nationwide SHI-physicians outpatient claims data confirms increased risk

氟喹诺酮类药物的使用与主动脉瘤或主动脉夹层:一项基于德国全国性医疗保险(SHI)医生门诊索赔数据的队列研究证实风险增加。

阅读:2

Abstract

BACKGROUND: Acute aortic dissection (AAD) is a potentially life-threatening condition with an annual incidence of approximately 6.0–16.9 per 100,000 inhabitants. Fluoroquinolone use has been identified as a potential risk factor for aortic aneurysm/acute aortic dissection (AA/AAD), leading to restrictions on their clinical indication. As adverse drug reactions (ADRs) are a key issue in pharmacovigilance, this study addresses two questions: First, can the reported association between fluoroquinolones and AA/AAD be confirmed in German routine healthcare data? Second, is there an association with the risk of AA/AAD, considering the role of underlying infections? METHODS: We analyzed prescription and diagnostic data of statutory health insurance patients in Germany (~ 87% of the population) between 2009 and 2017. Patients treated with fluoroquinolones were compared with a propensity score-matched control group treated with other non-fluoroquinolone antibiotics. Cox proportional hazards models were used to estimate hazard ratios (HRs) for aortic aneurysm and dissection. Graph-theoretic methods were applied to identify morbidity-related variables for propensity score matching. RESULTS: Patients treated with fluoroquinolones had a higher risk of developing AA/AAD compared to those treated with other antibiotics (HR: 1.56). In sensitivity analyses excluding patients with pneumonia or aortic dissection, the risk was slightly reduced (HR: 1.43). The HR remained elevated even when adjusted for underlying infections, sex and age (HR: 1.48), indicating a potential drug-related effect independent of specific infections. CONCLUSIONS: Fluoroquinolone use is associated with an increased risk of aortic aneurysm and dissection. These findings highlight the value of routine healthcare data in detecting adverse drug reactions and underline the need for careful risk–benefit evaluation when prescribing fluoroquinolones. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-025-05163-z.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。